- a) <u>a first</u> part of the cells of the preproduction batch is used for the preparation of at least one production batch, and
- b) the remaining part of the cells of the preproduction batch is used as a seed for the preparation of at least one subsequent preproduction batch.

Claim 2, line 1: replace "Method" with -- A method --; and

line 2: insert after "a)" and before "part" -- the first --.

- -- 7. The method according to Claim 1, wherein a first preproduction batch is prepared from a working seed stock by at least one passage step.
- 8. The method according to Claim 2, wherein a first preproduction batch is prepared from a working seed stock by at least one passage step.
- 9. The method according to Claim 1, wherein the cells are anchorage dependent.
- derived from hamsters (CHO, BHK-1), monkeys (Vero), bovines (MDNK), canines (MDCK), humans (CaCo, A431), or chickens (CEF).

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L. L. P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

National Phase of PCT/EP98/08522 Attorney Docket No. 01975.0025-00000

- 11. The method according to Claim 2, wherein the cells are anchorage dependent, are grown on a substrate, and are released from said substrate prior to each transfer step.
- 12. The method according to Claim 11, wherein the substrate comprises particulate matter or a solid support.
- 13. The method according to Claim 12, wherein the solid support comprises hollow fibers or micro-carriers or macro-carriers in suspension.
- 14. The method according to Claim 11, wherein the cells are embedded in a carrier.
- 15. The method according to Claim 14, wherein the carrier is a Cytodex-3 micro-carrier.
- 16. The method according to Claim 11, wherein the cells are released from said substrate with a proteolytic enzyme.
- 17. The method according to Claim 16, wherein the proteolytic enzyme is trypsin.
- 18. The method according to Claim 16, wherein the cells are treated with PBS and/or EDTA prior to exposure to the proteolytic enzyme.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
8 DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

- 19. The method according to Claim 1, wherein the biological is a virus.
- 20. The method according to Claim 1, wherein the biological is a protein.
- 21. The method according to Claim 20, wherein the protein is an enzyme.
- 22. The method according to Claim 1, wherein:
 - a) the proportion of the cells of the preproduction batch used for the preparation of said at least one production batch ranges from 80% to 90%, and
 - b) the remaining proportion of the cells of the preproduction batch used as a seed for the preparation of said at least one subsequent preproduction batch ranges from 10% to 20%.
- 23. The method according to Claim 1, wherein the cells are parked at a certain passage number by exposure to an ambient temperature ranging from 17 to 32 degrees C.
- 24. The method according to Claim 23, wherein said parked cells are revitalised to log growth by raising the temperature and changing the culture media.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000